Once-daily dexlansoprazole improves quality of life for gastrosophageal reflux disease patients
MONDAY, Feb. 27 (HealthDay News) -- The majority of gastroesophageal reflux disease (GERD) patients who take twice-daily proton pump inhibitor (PPI) therapy, are able to successfully step down to management of heartburn with a daily dose of dexlansoprazole modified release (MR), according to a study published in the March issue of Clinical Gastroenterology and Hepatology.
Ronnie Fass, M.D., of the Southern Arizona VA Healthcare System in Tucson, and associates conducted a multicenter, single-blind study of 142 patients with GERD to determine if twice-daily PPI therapy for more than eight weeks could be phased down successfully to 30 mg once-daily dexlansoprazole MR and what the impact would be on health-related quality of life (QOL). Patients recorded heartburn in electronic diaries; heartburn was considered well-controlled if patients had an average of one symptom or fewer per week during the last four weeks of treatment. GERD-related symptoms and QOL were assessed using the Patient Assessment of Upper Gastrointestinal Disorders (PAGI) Symptom Severity Index and the PAGI-QOL, respectively.
The researchers found that, following step down from PPI therapy, heartburn remained well controlled in 125 patients (88 percent), and these patients were able to maintain their QOL and GERD-related symptom severity.
"Step-down management of GERD patients who have obtained heartburn symptom control on twice-daily dosing should be considered to reduce costs, possibly improve compliance, and reduce the risk of side effects associated with high-dose PPI use," the authors write.
Several authors disclosed financial ties to pharmaceutical and medical device companies, including Takeda, which funded the study and manufactures dexlansoprazole.
Full Text (subscription or payment may be required)